Evidence map›Paper›PMID 22654726›Full record

ArticleCurrent neuropharmacology2011

A role for calcineurin in Alzheimer's disease.

Lindsay C Reese, Giulio Taglialatela

Open access · bronzeAbstract read
In one paragraph

Article in Current neuropharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
2.9field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 136 citations in OpenAlex.

  1. Decoding the mechanisms of amyloid-β in synaptic toxicity.Journal of Alzheimer's disease : JAD · 2026
    Review
  2. Neuronal Calcium Signaling and Cytoskeletal Dynamics in Neurodegeneration.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Target the Heart: A New Axis of Alzheimer's Disease Prevention.Journal of dementia and alzheimer's disease · 2025
    Article
  8. Calcineurin inhibition may prevent Alzheimer disease in people with Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
  9. Review
  10. Article
  11. Article
  12. Role of Calmodulin in Neurodegeneration and Neuroprotection.Mini reviews in medicinal chemistry · 2025
    Review
  13. Chronic palmitoylethanolamide administrationFrontiers in cellular neuroscience · 2025
    Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Cytosolic calcium: Judge, jury and executioner of neurodegeneration in Alzheimer's disease and beyond.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2023
    Review
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Lindsay C ReeseDepartment of Neuroscience & Cell Biology, University of Texas Medical Branch at Galveston, Texas, 77555-1043, USA.
Giulio Taglialatela
The University of Texas Medical Branch at Galveston · US

Funding

PAIN, NOCICEPTION, AND THE AMYGDALAR01NS038261 · NINDS · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI Volker Neugebauer, Igor Ponomarev · 1999 to 2026
$8.7M
The Effects of Aberrant Calcineurin Activation by Oligomeric Amyloid BetaF31NS062558 · NINDS · UNIVERSITY OF TEXAS MED BR GALVESTON · PI REESE, LINDSAY CARMELITA · 2008 to 2010
$77k
NINDS NIH HHS F31 NS062558NINDS NIH HHS R01 NS038261
6 · The paper itself

Abstract

Alzheimer's disease (AD) is an incurable age-related neurodegenerative disorder characterized by profound memory dysfunction. This bellwether symptom suggests involvement of the hippocampus -- a brain region responsible for memory formation -- and coincidentally an area heavily burdened by hyperphosphorylated tau and neuritic plaques of amyloid beta (Aβ). Recent evidence suggests that pre-fibrillar soluble Aβ underlies an early, progressive loss of synapses that is a hallmark of AD. One of the downstream effects of soluble Aβ aggregates is the activation of the phosphatase calcineurin (CaN). This review details the evidence of CaN hyperactivity in 'normal' aging, models of AD, and actual disease pathogenesis; elaborates on how this could manifest as memory impairment, neuroinflammation, hyperphosphorylated tau, and neuronal death.

Indexed as

Alzheimersamyloid betacalcineurincalcium.

Identifiers

PMID22654726
PMCPMC3263462
OpenAlexW2044904524

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.